This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. U.S. companies are largely unprepared for AI's impending workforce disruption, with a ...

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach ...

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one ...

The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...

Unmanned Surface Vessel Division 12 (Sea Hunter) and 13 (Sea Hunter) conduct unit level training underway in San Diego Bay, California, May 1, 2025. US Navy photo The Navy’s portfolio acquisition ...

"Always reminds me of Niall for some reason," the Brit said of one track. By Hannah Dailey It may drive him crazy just how fast the night changes, but One Direction‘s music will always live on in ...

Samsung Electronics is reportedly working with multiple partners to develop production equipment for its seventh-generation 10nm-class (1d) DRAM process... Some subscribers prefer to save their log-in ...

The ability to control the movement of negatively charged particles (i.e., electrons) is central to the functioning of all modern electronic devices. This control is typically attained using a gate, ...

Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with ...

Cormorant Asset Management bought 5,800,000 Erasca shares in the first quarter, an estimated $68.55 million trade based on quarterly average pricing. The quarter-end position value rose by $93.84 ...